Table 1.

Comparative toxicities of vemurafinib, dabrafenib and trametinib reported in different randomized trials.

	Vemurafenib*$	Dabrafenib‡	Trametinib§	Dabrafenib + trametinib‖¶#
Rash	41 (9)	30 (0)	57 (8)	27 (0)
Cutaneous SCC	19 (19)	10 (4)	0	7 (5)
Diarrhoea	25 (<1)	NR	43 (0)	36 (2)
Pyrexia	NR	16 (3)	NR	51 (6)
Arthralgia	56 (6)	19 (<1)	NR	24 (0)
Fatigue	46 (3)	18 (1)	26 (4)	53 (4)
Cardiac	NR	NR	7 (1)	9 (0)
ILD/pneumonitis	NR	NR	2 (2)	1
Ophthalmologic	NR	NR	9 (<1)	2 (2)
Hypertension	NR	4 (0)	15 (12)	9 (2)
Hyperglycaemia	NR	49 (2)#	NR	58 (5)
Liver laboratory abnormalities:	36 (11)	26 (2) #	24 (2)	60 (2)
Alkaline phosphatase		11 (0) #	39 (3)	42 (4)
Alanine aminotransferase		0 (0) #	NR	15 (0)
Bilirubin		60 (2)#	60 (2)	60 (5)
Aspartate aminotransferase

Toxicities are expressed as percentage of all CTC grades (CTC grade 3/4). The data in this table are summarized from different trials and do not represent direct comparisons.

^*Chapman et al. [2011].

^$Larkin et al. [2014].

^‡Hauschild et al. [2012, 2013].

^§Flaherty et al. [2012b].

^‖Flaherty et al. [2012a].

^¶Long et al. [2014].

^#Data are a composite of phase I/II and III trial data since limited data are available from the phase III trial.

SCC, squamous cell carcinoma; ILD, interstitial lung disease; NR, not reported.